

Provider Notice

To: PerformCare MH Clinics, Psychiatrists and CRNPs
From: PerformCare
Date: April 24, 2024
Subject: MH 24 104: Spravato Billing Guidelines - UPDATE

Effective for dates of service 6/1/2024, providers should change the billing code modifier for Spravato post dosing observation as outlined in Appendix 1 (attached).

PerformCare implemented payment for the post dosage observation required to administer intranasal Esketamine, brand name Spravato in September 2023. Esketamine, (brand name Spravato) is both FDA and DHS approved to treat persons with treatment resistant depression. Spravato is covered by PA Medicaid PH - MCO drug formularies, but it requires prior approval from the PH MCO.

Spravato treatment consists of:

- 1) An assessment by a psychiatrist or advanced practitioner, or qualified health care professional same day, but prior to the Spravato dose administration, which can be billed to PerformCare with the appropriate E & M code if applicable.
- 2) The member then self-administers Spravato via nasal inhaler in the presence of the psychiatrist or advanced practitioner or qualified health care professional.
- 3) The members must then be observed for a minimum of two hours by a qualified health care professional billed to PerformCare per the description and rate in Appendix 1 attached.

We have also configured our system to add **Medicare Bundled codes** and **rates** to our system as described in Appendix 1 so that we can coordinate benefits for Spravato treatment for dual eligible members. While Medicare has adopted a bundled code and rate that includes the pre dose assessment, the cost of the Spravato medication and the post dosing observation, other primary insurers have plan specific requirements for the various treatment components and billing for the post Spravato dosing observation. There is no standard national code for the minimum of 2 hours of post administration observation of intranasal Esketamine.

Please contact your Account Executive if you have any questions about this Provider Notice.

cc: Lisa Hanzel, Executive Director, PerformCare
Scott Suhring, Capital Area Behavioral Health Collaborative
Missy Wileman, Tuscarora Managed Care Alliance
PerformCare Account Executives

Appendix 1

These codes are available to Provider types 08/110 - MH OP clinics, 31/339 - Psychiatrists, and 09/103 – CRNPs **through dates of service 5/31/2024**

Code	Modifier	Description
G2082	WA	A minimum of 2 hours of post administration observation of intranasal esketamine (Spravato) 56 mg or less
G2083	WA	A minimum of 2 hours of post administration observation of intranasal esketamine (Spravato) > 56 mg

These codes are available to Provider types 08/110 - MH OP clinics, 31/339 - Psychiatrists, and 09/103 – CRNPs **starting with dates of service 6/1/2024**

Code	Modifier	Description
G2082	UD	A minimum of 2 hours of post administration observation of intranasal esketamine (Spravato) 56 mg or less
G2083	UD	A minimum of 2 hours of post administration observation of intranasal esketamine (Spravato) > 56 mg

We also configured our system to add these Medicare **Bundled codes** and rates to our system so we can accept Medicare Crossover claims for Spravato (Esketamine)

HCPCS Code	Short Description
G2082	Visit esketamine 56m or less

HCPCS Code	Short Description
G2083	Visit esketamine, > 56m